Abstract
Objectives
Diabetes mellitus is a major public health problem. Hemoglobin A1c (HbA1c) is a key laboratory parameter in the management of diabetes patients. However, in diabetes monitoring, interpretation of HbA1c results is hampered by the important interindividual variation in red blood cell (RBC) life span. Furthermore, HbA1c only slowly responds to changes in glucose metabolism. Besides HbA1c, there exists a labile HbA1c fraction (l-HbA1c), exhibiting much faster kinetics. As both HbA1c and l-HbA1c are measured by modern standard chromatography, we explored the possibilities of using the l-HbA1c fraction for monitoring glycemia.
Methods
l-HbA1c and HbA1c fractions were simultaneously assayed on a Tosoh G8 analyzer and expressed as %. l-HbA1c results were compared with serum glucose and HbA1c. Concomitantly, RBC distribution width (RDW) was determined on a Sysmex SN analyzer as a marker for erythrocyte life span.
Results
l-HbA1c could be measured with between-run coefficient of variations (CVs) between 2.2 and 2.3%. l-HbA1c correlated with both glycemia (r=0.80) and HbA1c results (r=0.73). In a multiple regression model (r2=0.752), glycemia and HbA1c were the most determining factors. To a lesser extent, RDW correlated with l-HbA1c (r=0.158). Furthermore, the l-HbA1c/HbA1c ratio weakly positively correlated with RDW (r=0.247).
Conclusions
L-HBA1c represents an additional marker for monitoring the rapid occurrence of glycemic disorders that escape detection when using only HbA1c and blood glucose. RDW can be used as an indicator of atypical RBCs life span, in which the l-HbA1c fraction may be helpful.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Not applicable.
-
Ethical approval: Not applicable.
References
1. Bergman, M, Abdul-Ghani, M, DeFronzo, RA, Manco, M, Sesti, G, Fiorentino, TV, et al.. Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract 2020;165:108233. https://doi.org/10.1016/j.diabres.2020.108233.Search in Google Scholar PubMed PubMed Central
2. Kohzuma, T, Tao, X, Koga, M. Glycated albumin as biomarker: evidence and its outcomes. J Diabetes Complicat 2021;35:108040. https://doi.org/10.1016/j.jdiacomp.2021.108040.Search in Google Scholar PubMed
3. León-Triana, O, Calvo, GF, Belmonte-Beitia, J, Rosa Durán, M, Escribano-Serrano, J, Michan-Doña, A, et al.. Labile haemoglobin as a glycaemic biomarker for patient-specific monitoring of diabetes: mathematical modelling approach. J R Soc Interface 2018;15:20180224.10.1098/rsif.2018.0224Search in Google Scholar PubMed PubMed Central
4. Corbé-Guillard, E, Jaisson, S, Pileire, C, Gillery, P. Labile hemoglobin A1c: unexpected indicator of preanalytical contraindications. Clin Chem 2011;57:340–1. https://doi.org/10.1373/clinchem.2010.152819.Search in Google Scholar PubMed
5. Morel, F, Henquet, S, Fondefréde, M. Labile or not labile: that is the question. Ann Biol Clin 2013;71:373–6. https://doi.org/10.1684/abc.2013.0829.Search in Google Scholar PubMed
6. Loh, TP, Peng, WK, Chen, L, Sethi, SK. Application of smoothed continuous labile haemoglobin A1c reference intervals for identification of potentially spurious HbA1c results. J Clin Pathol 2014;67:712–6. https://doi.org/10.1136/jclinpath-2014-202346.Search in Google Scholar PubMed
7. Koga, M, Kurebayashi, S, Murai, J, Saito, H, Miyazaki, A. Degree of discrepancy between HbA1c and glycemia in variant hemoglobin is smaller when HbA1c is measured by new-type Arkray HPLC compared with old-type HPLC. Clin Biochem 2014;47:123–5. https://doi.org/10.1016/j.clinbiochem.2013.09.019.Search in Google Scholar PubMed
8. Koga, M, Inada, S, Miyazaki, A. Identification of the presence of variant hemoglobin using a measurement of the labile HbA1c (# C) fraction. Ann Clin Lab Sci 2016;46:387–92.Search in Google Scholar
9. Cohen, RM, Franco, RS, Khera, PK, Smith, EP, Lindsell, CJ, Ciraolo, PJ, et al.. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008;112:4284–91. https://doi.org/10.1182/blood-2008-04-154112.Search in Google Scholar PubMed PubMed Central
10. Khera, PK, Smith, EP, Lindsell, CJ, Colleen Rogge, M, Haggerty, S, Wagner, DA, et al.. Use of an oral stable isotope label to confirm variation in red blood cell mean age that influences HbA1c interpretation. Am J Hematol 2015;90:50–5. https://doi.org/10.1002/ajh.23866.Search in Google Scholar PubMed PubMed Central
11. Nordin, G. Accuracy of HbA1c as monitored by external quality assessment and compared with patient mean values. J Diabetes Sci Technol 2018;12:771–9. https://doi.org/10.1177/1932296818785622.Search in Google Scholar PubMed PubMed Central
12. Jalali, MT, Bavarsad, SS, Hesam, S, Afsharmanesh, MR, Mohammadtaghvaei, N. Assessing agreement between the three common clinical measurement methods of HbA1c. J Diabetes Metab Disord 2020;19:273–9. https://doi.org/10.1007/s40200-020-00503-6.Search in Google Scholar PubMed PubMed Central
13. Park, SH, Park, CJ, Lee, BR, Kim, MJ, Han, MY, Cho, YU, et al.. Establishment of age-and gender-specific reference ranges for 36 routine and 57 cell population data items in a new automated blood cell Analyzer, Sysmex XN-2000. Ann Lab Med 2016;36:244–9. https://doi.org/10.3343/alm.2016.36.3.244.Search in Google Scholar PubMed PubMed Central
14. Alzahrani, N, Alouffi, S, Almutairi, K, Almutairi, M, Almutairi, T, Al Alwan, I, et al.. Can fasting blood sugar be used as an indicator of long-term diabetic control instead of estimated average glucose? Clin Lab 2020;66:12. https://doi.org/10.7754/Clin.Lab.2020.200324.Search in Google Scholar PubMed
15. Kawahara, R, Amemiya, T, Komori, T, Hirata, Y. The effect of blood glucose concentration on labile A1c in diabetic patients. Diabetes Care 1985;8:375–9. https://doi.org/10.2337/diacare.8.4.375.Search in Google Scholar PubMed
16. Salvagno, GL, Sanchis-Gomar, F, Picanza, A, Lippi, G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci 2015;52:86–105. https://doi.org/10.3109/10408363.2014.992064.Search in Google Scholar PubMed
17. Douglas, SW, Adamson, JW. The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 1975;45:55–65. https://doi.org/10.1182/blood.v45.1.55.55.Search in Google Scholar
18. Ricós, C, Alvarez, V, Cava, F, García-Lario, JV, Hernández, A, Jiménez, CV, et al.. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491–500.10.1080/00365519950185229Search in Google Scholar PubMed
19. Maese, JM, Fernández-Riejos, P, Sánchez Mora, C, de Toro, M, Menéndez Valladares, P, González-Rodriguez, C. Evaluation of Bio-Rad D-100 HbA1c analyzer against Tosoh G8 and Menarini HA-8180V Pract. Lab Med 2016;5:57–64.10.1016/j.plabm.2016.05.002Search in Google Scholar
20. Lin, MJ, Hoke, C, Ettinger, B, Coyne, RV. Technical performance evaluation of BM/Hitachi 747-200 serum fructosamine assay. Clin Chem 1996;42:244–8. https://doi.org/10.1093/clinchem/42.2.244.Search in Google Scholar
21. Weykamp, C, John, WG, Mosca, A, Hoshino, T, Little, R, Jeppsson, JO, et al.. The IFCC reference measurement system fo HbA1c: a 6-year progress report. Clin Chem 2008;54:240–8. https://doi.org/10.1373/clinchem.2007.097402.Search in Google Scholar PubMed
22. Nayak, AU, Holland, MR, Macdonald, DR, Nevill, A, Singh, BM. Evidence for consistency of the glycation gap in diabetes. Diabetes Care 2011;34:1712–6. https://doi.org/10.2337/dc10-1767.Search in Google Scholar PubMed PubMed Central
© 2022 Walter de Gruyter GmbH, Berlin/Boston
